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Biomarkers of Dairy Fatty Acids and Risk of Cardiovascular Disease in
the Multi-Ethnic Study of Atherosclerosis
Marcia C. de Oliveira Otto, PhD; Jennifer A. Nettleton, PhD; Rozenn N. Lemaitre, PhD; Lyn M. Steffen, PhD; Daan Kromhout, PhD;
Stephen S. Rich, PhD; Michael Y. Tsai, PhD; David R. Jacobs, Jr, PhD; Dariush Mozaffarian, MD, PhD
Background-—Evidence regarding the role of dairy fat intake in cardiovascular disease (CVD) has been mixed and inconclusive.
Most earlier studies have used self-reported measures of dietary intake and focused on relatively racially homogeneous
populations. Circulating biomarkers of dairy fat in a multiethnic cohort provide objective measures of dairy fat intake and facilitate
conclusions relevant to populations with different diets and susceptibility to CVD.
Methods and Results-—In a multiethnic cohort of 2837 US adults aged 45 to 84 years at baseline (2000–2002), phospholipid fatty
acids including 15:0, 14:0, and trans-16:1n7 were measured using standardized methods, and the incidence of CVD prospectively
adjudicated. Self-reported whole-fat dairy and butter intakes had strongest associations with 15:0, rather than 14:0 or
trans-16:1n7. In multivariate models including demographics and lifestyle and dietary habits, each SD-unit of 15:0 was associated
with 19% lower CVD risk (hazard ratio [95% CI] 0.81 [0.68 to 0.98]) and 26% lower coronary heart disease (CHD) risk (0.74 [0.60 to
0.92]). Associations were strengthened after mutual adjustment for 14:0 and trans-16:1n-7 and were similar after adjustment for
potential mediators. Plasma phospholipid 14:0 and trans-16:1n-7 were not signiﬁcantly associated with incident CVD or CHD. All
ﬁndings were similar in white, black, Hispanic, and Chinese American participants.
Conclusion-—Plasma phospholipid 15:0, a biomarker of dairy fat, was inversely associated with incident CVD and CHD, while no
association was found with phospholipid 14:0 and trans-16:1n-7. These ﬁndings support the need for further investigation of CVD
effects of dairy fat, dairy-speciﬁc fatty acids, and dairy products in general. ( J Am Heart Assoc. 2013;2:e000092 doi: 10.1161/
JAHA.113.000092)
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T he role of dairy products, and especially dairy fat intake, incardiovascular health is controversial. Some epidemio- logical studies have suggested beneﬁcial effects of low-fat dairyconsumption on hypertension1–3 and stroke risk,4,5 and low-fat
dairy consumption is a component of the beneﬁcial Dietary
Approaches to Stop Hypertension (DASH) diet.6 Conversely,
consumption of whole-fat dairy is discouraged due to potential
adverse effects of saturated fat on coronary heart disease
(CHD). A recent meta-analysis that included >250 000 partic-
ipants in 6 prospective observational studies found no evidence
of harmful associations between self-reported overall milk
consumption and incidence of CHD or stroke (pooled relative
risk (RR) [95% CI] for each 200 mL/day of 1.00 [0.96 to 1.04]
for CHD and 0.87 [0.72 to 1.07] for stroke).7 This pooled
meta-analysis also found no differences in associations of
self-reported total, whole-fat, or low-fat/nonfat dairy products
and CHD risk, but reported data on these dairy subgroups were
restricted to fewer studies. Consequently, based on current
evidence, whether dairy fat is associated with cardiovascular
disease (CVD) risk remains unclear.
Possible explanations for the inconclusive ﬁndings could
relate to (1) competing beneﬁts of certain ingredients in
nonfat dairy products, such as protein, calcium, and phos-
phorous, versus harms of saturated fat in dairy fat or
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(2) offsetting beneﬁcial components of speciﬁc factors in
dairy fat, such as vitamin D or dairy-speciﬁc fatty acids or (3)
potential misclassiﬁcation or reporting bias of self-reported
dietary assessment, which could attenuate measures of
association or cause bias.
Compared with self-reported dietary estimates, circulating
fatty acid biomarkers such as pentadecanoic acid (15:0) and
trans-palmitoleic acid (trans-16:1n-7) cannot be synthesized
by humans and are useful objective biomarkers of dairy fat
consumption.8–11 Dairy products also contain myristic acid
(14:0), but endogenous synthesis of this fatty acid makes its
circulating levels less useful as a biomarker of dairy fat
consumption.12 The evaluation of objective biomarkers of
dairy fat may improve accuracy in dietary assessment
methods and help elucidate associations between dairy and
cardiovascular health.
Relatively few studies have evaluated associations between
biomarkers of dairy fat and incidence of CVD.8,9,13–15 In
addition, none of these prior studies have investigated
multiethnic populations with diverse dietary behaviors and
susceptibilities to CVD. To address these gaps in knowledge
about potential effects of dairy fat on CVD, we prospectively
assessed the associations of plasma phospholipid 15:0,
trans-16:1n-7, and 14:0 with incident total CVD and CHD in
the Multi-Ethnic Study of Atherosclerosis (MESA). Measures of
plasma 17:0, another potential biomarker of dairy fat, were not
available in MESA. We hypothesized that circulating biomar-
kers of dairy fat would be inversely associated with CVD risk.
Methods
Design and Population
Details of MESA, a prospective cohort study designed to
identify risk factors associated with subclinical CVD develop-
ment and progression in multiple US races/ethnicities, have
been published.16 Between 2000 and 2002, the study
enrolled and performed baseline examinations in 6814 adults
(38% whites, 28% blacks, 22% Hispanics, and 12% Chinese
Americans) aged 45 to 84 years in 6 US communities:
Baltimore (city and county), MD; Chicago, IL; Forsyth County,
NC; New York, NY; Los Angeles County, CA; and St Paul, MN.
All participants were free of clinical CVD at baseline.
Follow-up cohort examinations were conducted in 2002–
2003, 2004–2005, 2005–2007, and 2010–2011. Protocols
were approved by local institutional review boards, and all
participants gave written informed consent. Plasma phospho-
lipid fatty acids were measured at baseline in a subset of
2856 participants randomly selected from within each race/
ethnicity stratum to provide similar proportions of partici-
pants. There were no material differences when comparing
baseline characteristics of participants with and without
biomarker measurement in each race/ethnicity group. After
the exclusion of 43 participants with missing data on incident
CVD, 2837 participants were included in the present analysis,
including equal proportions of black (n=697), Asian (of Chinese
descent, n=711), Hispanic (n=705), and white (n=724)
participants.
Analysis of Plasma Phospholipid Fatty Acids
Fasting blood samples were collected at the baseline
examination and stored at 70°C according to standardized
protocols.16,17 Fatty acids were extracted from EDTA plasma
using a chloroform/methanol extraction method,18 with
phospholipids separated from cholesterol esters, triglyce-
rides, and free fatty acids by using thin layer chromatography.
Forty-one individual phospholipid fatty acids were derivatized
to methyl esters and separated by using gas chromatography
equipped with ﬂame ionization detection, quantiﬁed as a
percentage of total fatty acids. In the present analysis, we
focused on 14:0, 15:0, and trans-16:1n-7. For each fatty acid,
the automated (computer software) limit of detection was
0.03%. Lab CVs across a range of control sample concentra-
tions (very low to high) were 11.6% for 14:0, 14.5% for 15:0,
and 29.5% for trans-16:1n-7. Lab CVs excluding very low
control sample concentrations (≤0.05%) were 5.7% for 14:0,
7.7% for 15:0, and 10.9% for trans-16:1n-7.
Covariates
Information on sociodemographics, medical history, medica-
tion use, and smoking status and history was obtained at
baseline using interviewer-administered and self-completed
questionnaires. Blood lipid levels were measured using
standardized methods as previously described.19 Anthropo-
metric measurements were performed using standard proce-
dures. Resting seated blood pressure was measured 3 times
(Dinamap model Pro 100 automated oscillometric sphygmo-
manometer, Critikon, Tampa, FL), with mean of the last 2
measurements used for analyses. Physical activity was
assessed using the MESA Typical Week Physical Activity
Survey,20 a validated semiquantitative questionnaire adapted
from the Cross-Cultural Activity Participation Study21 that
captures time and frequency of various physical activities
during a typical week in the previous month. Usual dietary
intake over the previous year was assessed at baseline using
a Block-type,22 120-item food frequency questionnaire, mod-
iﬁed to include Chinese foods.23 Food questions from the FFQ
were categorized into food groups (eg, salty snacks, desserts,
processed meats) as previously described.24 Nutrient intakes
were estimated by multiplying food frequency and serving size
by speciﬁc nutrient content in each food. Criterion validity of
macronutrient intake estimates has been demonstrated using
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baseline plasma lipid measurements.25 Intakes of food-spe-
ciﬁc saturated fat were estimated by summing saturated fat
intake from selected sources (ie, dairy, meat, butter, and plant
sources) as previously described.26 Food frequency (servings
per day) was standardized to the medium portion size (ie,
frequencies from participants selecting small or large serving
sizes were multiplied by the ratio of small/medium [0.5] or
large/medium [1.5], respectively).
Ascertainment of Incident CVD
Information on potential CVD events was obtained during each
cohort examination and by follow-up calls to each participant,
which occurred every 9 to 12 months. Reported events were
evaluated and conﬁrmed by a centralized medical end points
committee based on medical record abstractions, death
certiﬁcates, autopsy reports, and/or obituaries.27,28 Medical
records were obtained for 98% of reported hospitalized events
and 95% of outpatient procedures.29 Total CVD events were
deﬁned as the incidence of any of the following: myocardial
infarction, resuscitated cardiac arrest, CHD death, other
atherosclerotic death, deﬁnite and probable angina, stroke, or
other CVD death. CHD events comprised myocardial infarction,
resuscitated cardiac arrest, CHD death, and deﬁnite and
probable angina. In sensitivity analyses, we also assessed
“hard” CVD events (ie, excluding deﬁnite and probable angina).
Statistical Analysis
We evaluated dairy-speciﬁc phospholipid fatty acids continu-
ously as percentage of total fatty acids and as categorical
variables in quintiles of each fatty acid. We used multivariate
regression models adjusting for demographic, lifestyle and
other dietary covariates to estimate differences in phospho-
lipid fatty acids associated with 1 daily serving of potential
dietary sources in the MESA population (ie, whole- and low-fat
dairy products, processed and unprocessed meats, French
fries, salty snacks, bakery desserts). We assessed the
adjusted Spearman correlations among 14:0, 15:0, and
trans-16:1n7 fatty acids and their potential dietary sources
in the MESA population, adjusting for demographics and
lifestyle and dietary factors. We used linear regression to
assess associations of dairy fatty acids with CVD risk factors.
Multivariable-adjusted Cox proportional hazards models esti-
mated hazard ratios (HRs) of incident CVD, with time at risk
until the ﬁrst CVD event, death, or last follow-up in 2009–
2010. We found no evidence of violation of the proportional
hazard assumption on the basis of Schoenfeld residuals or the
Wald test for an interaction between the exposures of interest
and follow-up time. In addition, we found no evidence of
nonlinear relationships between each fatty acid and the
outcomes of interest based on restricted cubic spline
analysis.30 We used serial models to adjust for potential
confounding, with covariates selected based on biologic
interest, established relationships with CVD risk, associations
with exposures/outcomes in the current dataset, and the
effects of their inclusion on the b coefﬁcient for the risk
estimates of interest. We found no evidence of multicollin-
earity based on variance inﬂation factor analyses. Multivar-
iate-adjusted models included age (years), sex, race/ethnicity
(non-Hispanic whites, blacks, Hispanics, and Chinese Amer-
icans), ﬁeld center (6 sites), education (<high school, high
school, >high school), cigarette smoking (never, current, or
former; and pack-years of cigarette smoking), alcohol (g/day),
physical activity (eg, walking for exercise, sports/dancing, and
conditioning activities in metabolic equivalents per minute/
week), whole-fat dairy (servings/day), processed and unpro-
cessed meat (servings/day), total energy intake (kcal/day),
ﬁber (g/day), and fruits and vegetables (servings/day).
Subsequently, we additionally included simultaneous adjust-
ment for each dairy fat biomarker (14:0, 15:0, and
trans-16:1n7).
We separately evaluated the inﬂuence of factors that could
be potential confounders or mediators of the associations of
interest, including body mass index (BMI) (kg/m2), diabetes
(no, impaired fasting glucose, diabetes), hypertensive medi-
cation use (yes/no), lipid-lowering medication use (yes/no),
and LDL cholesterol (mg/dL).
We imputed missing covariate data (<2% for most lifestyle
factors; 8% to 12% for dietary factors) using single imputation
(SAS proc MI, SAS Institute) based on age, sex, race/
ethnicity, education, physical activity, BMI, smoking status,
LDL cholesterol, HDL cholesterol, lipid-lowering medication
use, and diabetes mellitus; results were similar when we used
multiple imputation or excluded missing values. All P values
were 2 sided, with a=0.05. Analyses were conducted with
SAS version 9.3 (SAS Institute).
Results
At baseline, mean (SD) age was 61.5 (10.2) years, mean (SD)
BMI was 27.9 (5.5) kg/m2, and 13% of participants had
prevalent diabetes (Table 1). The mean levels of 14:0, 15:0,
and trans-16:1n7 were each relatively low (<1% of fatty acids),
consistent with reports in other cohorts.8,14 The mean (SD)
self-reported consumption of total dairy was 1.5 (2.0) servings
per day, equally distributed between low-fat and whole-fat
dairy products.
In multivariate analyses adjusting for sociodemographics,
lifestyle, and dietary factors, higher concentrations of plasma
phospholipid 15:0 were associated with younger age, white
race, lower BMI, and nonsmoking status at baseline (Table S2).
Among self-reported dietary factors, plasma phospholipid
15:0 was most strongly associated with consumption of
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high-fat dairy products (Figure). For example, each additional
daily serving of regular cheese, whole-fat milk, and butter was
associated with a 44%, 11%, and 23% SD increase in 15:0
concentrations, respectively. A generally similar pattern was
observed for 14:0, but with much smaller differences in
circulating levels for a similar self-reported intake of dairy
products. In contrast, greater consumption of margarine,
French fries, and bakery desserts was associated with higher
concentrations of trans-16:1n7, suggesting that circulating
phospholipid concentrations of this fatty acid in the MESA
cohort were mostly derived from food sources of industrial-
ized trans-fat. When we evaluated overall estimated dairy fat
consumption, each additional g/day was associated with 3%
SD increase in 15:0, 2% SD increase in 14:0, and no increase
in trans-16:1n7. Consistently, we observed stronger partial
correlations between high-fat dairy products and 15:0 com-
pared with other dairy subgroups (Table S1). We found no
major differences in correlations with dairy foods across
race/ethnicity groups, except for a higher correlation
between dairy and trans-16:1n7 in Chinese Americans and a
higher correlation between butter intake and 15:0 in whites
(data not shown).
Cross-sectional Associations of Dairy Fatty Acid
Biomarkers With CVD Risk Factors
In multivariable-adjusted analyses, higher plasma phospholipid
15:0 and trans-16:1n7 levels were signiﬁcantly associated with
lower plasma triglycerides and lower measures of both systolic
and diastolic blood pressures (Table 2). In contrast, higher
14:0 was positively associated with plasma triglycerides, blood
pressure, and total:HDL cholesterol, which has been suggested
to be an useful predictor of CHD events.31 Positive association
between 14:0 and triglycerides suggests this fatty acid
originated at least in part from endogenous synthesis, which
is inﬂuenced by excessive intake of dietary carbohydrates.
Higher plasma phospholipid trans-16:1n7 was also associated
with higher LDL cholesterol levels in MESA. No cross-sectional
associations were observed between dairy-fat markers and
HDL cholesterol. Additional adjustment for potential dietary
confounders did not materially change cross-sectional associ-
ations of dairy fatty acids and CVD risk factors.
Prospective Associations of Dairy Fatty Acid
Biomarkers With Incident CVD
During 19 778 person-years of follow-up between 2000 and
2010, 189 new CVD cases were diagnosed among partici-
pants included in our analyses. In multivariate models
adjusting for sociodemographics, lifestyle, and dietary
factors, each higher SD-unit of plasma phospholipid 15:0
(SD=0.05% difference in total fatty acid concentration) was
Table 1. Baseline Characteristics of Multi-Ethnic Study of
Atherosclerosis Participants (N=2837)
Characteristics
Mean age (SD), y 61.5 (10.2)
Woman, % 53
Race/ethnicity, %
Whites 25.5
Hispanic 24.8
Chinese American 25.1
Blacks 24.6
Education, %
Less than high school 21.6
High school 18.1
Some college/college degree 60.3
Current smokers, % 13.7
Physical activity (MET: min/week)
Sedentary leisure 1632 (1110)
Active leisure 2316 (2786)
BMI, kg/m2 27.9 (5.5)
Diabetes at baseline, % 13.1
Circulating fatty acids, % of total FA
Myristic acid 14:0 0.26 (0.08)
Pentadecanoic acid 15:0 0.17 (0.05)
trans-Palmitoleic acid (trans-16:1n-7) 0.05 (0.03)
Mean (SD) food intakes, serving/day
Total dairy 1.5 (2.0)
Low-fat dairy 0.8 (1.4)
Whole-fat dairy 0.7 (1.2)
Processed meat 0.2 (0.3)
Unprocessed meat 0.4 (0.5)
Fried potato 0.1 (0.2)
Salty snacks 0.2 (0.4)
Desserts 0.2 (0.5)
Margarine 0.2 (0.4)
Butter 0.1 (0.3)
Fruits and vegetables 3.3 (2.6)
Fiber, g/day 17.5 (6.1)
Values are mean (SD) for continuous variables and percent for categorical variables.
Whole-fat dairy included whole milk, cheese, whole-fat yogurt, and ice cream. Low-fat dairy
included 2% milk, 1%/skim milk, and cottage or ricotta cheese. Processed meats included
ham, hot dogs, bologna, salami, lunchmeats, liver, sausage, chorizo, scrapple, and bacon.
Unprocessed red meat included hamburger; cheeseburger; meatloaf; hash; beef, pork, or
lamb steaks; roasts; barbeque or ribs; and red meat in stir-fried and other mixed dishes.
Salty snacks included potato, corn, or tortilla chips; crackers; pretzels; and popcorn.
Desserts included white and chocolate doughnuts, cookies, cakes, brownies, candy,
pastries, Pop-Tarts, Chinese desserts, Mexican desserts, pies, pudding, custard, and ﬂan.
Fruits and vegetables included peaches, apricots, nectarines, plums, cantaloupe, mango,
papaya, strawberries, blueberries, other berries, apples, applesauce, pears, bananas,
plantains, oranges, grapefruit, tangerines, kiwi, dried fruits, tossed salad (with spinach,
Romaine, or dark greens), cooked spinach, turnip greens, collards, broccoli, cabbage,
cauliﬂower, Brussels sprouts, sauerkraut, kimchi, carrots, winter squash, acorn squash,
sweet potatoes, yams, green beans, peas, snow peas, squash, zucchini, asparagus, and
tomatoes. MET indicates metabolic equivalent; BMI, body mass index; FA, fatty acid.
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associated with a 19% lower risk of CVD (HR 0.81, 95% CI 0.68
to 0.98) (Table 3). This association was similar after further
simultaneous adjustment for plasma 14:0 and trans-16:1n7
(HR 0.76, 95% CI 0.61 to 0.93). This association was also not
appreciably altered by further adjustment for estimated
dietary intakes of calcium, phosphorous, vitamin D, carbohy-
drate, and protein or for total plasma phospholipid trans-fatty
acids (data not shown). When circulating 15:0 was evaluated
continuously, associations were similar to those of quintile
analyses, especially HRs for extreme quintiles, which are less
likely to be inﬂuenced by exposure misclassiﬁcation. Associ-
ations were similar across the 4 race/ethnicity groups (HR
[95% CI] of CVD for each SD-unit increase of 15:0 [model 2]:
0.78 [0.58 to 1.05] in whites, 0.69 [0.45 to 1.07] in blacks,
0.89 [0.63 to 1.26] in Hispanics, and 0.85 [0.45 to 1.61] in
Chinese Americans). Similarly, associations did not differ
between women (HR 0.80, 95% CI 0.60 to 1.08) and men (HR
0.81, 95% CI 0.64 to 1.02). In contrast, plasma phospholipid
14:0 and trans-16:1n7 were not associated with incident CVD.
Associations of trans-16:1n7 were similar after further
adjustment for other sources of trans-fat in this cohort, such
as bakery desserts, salty snacks, and French fries (HR [95%
CI] across quintiles of trans-16:1n7 were 1.04 [0.63 to 1.72],
1.30 [0.80 to 2.14], 1.35 [0.80 to 2.27], and 0.99 [0.58 to
1.70]; P-trend=0.86; HR [95% CI] for 1-SD increase in
trans-16:1n7: 0.97 [0.82 to 1.13]).
Figure. Multiadjusted differences in circulating markers of dairy according to 1 serving per day of selected food intakes in the Multi-Ethnic Study
of Atherosclerosis. Bars represent multivariate-adjusted differences and 95% CI in plasma phospholipid fatty acid levels associated with each
higher serving per day intake for selected foods, expressed as SD-units (1 SD=0.08%, 0.05%, and 0.03% difference in 14:0, 15:0, and trans-16:1n7
fatty acid levels, respectively). Error bars represent 95% CI. Multivariate-adjusted models included ﬁeld center, age (years), sex, race/ethnicity
(non-Hispanic whites, blacks, Hispanics, and Chinese Americans), education (<high school, high school, >high school), cigarette smoking (never,
current, or former smokers and pack-years of cigarette smoking), alcohol (g/day), physical activity (active and inactive leisure in metabolic
equivalents per minute/week), body mass index (kg/m2), diabetes at baseline (no, impaired fasting glucose, yes), weekly use of dietary
supplement (yes, no), energy intake (kcal/day), ﬁber intake (g/day), unprocessed meat (serving/day), fruits and vegetables, and mutual
adjustment for all groups presented. Whole-fat dairy included whole milk, cheese, and whole-fat yogurt. Low-fat dairy included 2% milk, 1%/skim
milk, cottage or ricotta cheese, and low-fat yogurt. Processed meats included ham, hot dogs, bologna, salami, lunchmeats, liver, sausage, chorizo,
scrapple, and bacon. Unprocessed red included meat hamburger; cheeseburger; meatloaf; hash; beef, pork, or lamb steaks; roasts; barbeque or
ribs; and red meat in stir-fried and other mixed dishes. Salty snacks included potato, corn, or tortilla chips; crackers; pretzels; and popcorn.
Desserts included white and chocolate doughnuts, cookies, cakes, brownies, candy, pastries, PopTarts, Chinese desserts, Mexican desserts, pies,
pudding, custard, and ﬂan. Fruits and vegetables included peaches, apricots, nectarines, plums, cantaloupe, mango, papaya, strawberries,
blueberries, other berries, apples, applesauce, pears, bananas, plantains, oranges, grapefruit, tangerines, kiwi, dried fruits, tossed salad (with
spinach, Romaine, or dark greens), cooked spinach, turnip greens, collards, broccoli, cabbage, cauliﬂower, Brussels sprouts, sauerkraut, kimchi,
carrots, winter squash, acorn squash, sweet potatoes, yams, green beans, peas, snow peas, squash, zucchini, asparagus, and tomatoes.
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Prospective Associations of Dairy Fatty Acid
Biomarkers With Incident CHD
A total of 146 new CHD cases were diagnosed during
follow-up. Plasma phospholipid 15:0 was inversely associated
with risk of CHD (Table 4). For example, each SD-unit of 15:0
was associated with a 26% lower CHD risk (HR 0.74, 95% CI
0.60 to 0.92). No associations were seen between plasma
phospholipid 14:0 or trans-16:1n7 and incident CHD.
Sensitivity Analyses
Findings were generally similar in sensitivity analyses exclud-
ing probable and deﬁnite angina (Table S3). For example, in
the multivariable model, plasma 15:0 was inversely associ-
ated with incident CVD (HR [95% CI] for each SD of 15:0 were
0.80 [0.64 to 0.99]) and CHD (0.77 [0.59 to 1.01]). These
associations were slightly attenuated and no longer statisti-
cally signiﬁcant after further simultaneous adjustment for
Table 2. Multivariable-Adjusted Cross-sectional Associations of Dairy Plasma Phospholipid With CVD Risk Factors in the
Multi-Ethnic Study of Atherosclerosis (N=2837)
Quintiles of Plasma Phospholipid Fatty Acids
P Trend*1 2 3 4 5
14:0
Median, % of total fatty acids 0.17 0.21 0.25 0.3 0.38
Systolic BP, mm Hg† 125.4 (0.8) 126.2 (0.8) 124.2 (0.7) 126.2 (0.9) 128.5 (0.9) 0.02
Diastolic BP, mm Hg† 71.7 (0.4) 71.6 (0.4) 71.3 (0.4) 72.4 (0.4) 72.7 (0.4) 0.03
Triglycerides, mg/dL‡ 117.9 (2.9) 130.2 (4) 134.0 (2.9) 149 (3.8) 152.7 (4.9) <0.0001
HDL-C, mg/dL‡ 50.8 (0.5) 50.9 (0.5) 50.1 (0.5) 50.5 (0.5) 50.7 (0.6) 0.77
LDL-C, mg/dL‡ 115.5 (1.2) 118.5 (1.4) 116.8 (1.3) 116.6 (1.3) 117.7 (1.4) 0.58
Total:HDL-C‡ 4.0 (0.1) 4.1 (0.1) 4.1 (0.1) 4.2 (0.1) 4.2 (0.1) <0.01
CRP, mg/L§ 3.6 (0.3) 3.9 (0.3) 3.4 (0.2) 3.5 (0.2) 3.6 (0.2) 0.54
15:0
Median, % of total fatty acids 0.12 0.14 0.16 0.19 0.24
Systolic BP, mm Hg† 129.1 (0.8) 126.5 (0.8) 125.3 (0.7) 124.6 (0.8) 123.9 (0.9) <0.0001
Diastolic BP, mm Hg† 73.3 (0.4) 71.9 (0.4) 71.7 (0.4) 71.6 (0.4) 70.7 (0.4) <0.0001
Triglycerides, mg/dL‡ 146.4 (3.7) 137.9 (4.3) 135.9 (3.6) 130.3 (3.5) 124.5 (3.6) <0.01
HDL-C, mg/dL‡ 50.6 (0.5) 51.1 (0.5) 49.8 (0.5) 50.9 (0.5) 50.7 (0.6) 0.89
LDL-C, mg/dL‡ 117.2 (1.3) 116.6 (1.3) 117.4 (1.2) 117.8 (1.4) 115.9 (1.4) 0.64
Total:HDL-C‡ 4.14 (0.1) 4.1 (0.1) 4.2 (0.1) 4.1 (0.1) 4 (0.1) 0.22
CRP, mg/L§ 3.5 (0.2) 4.1 (0.3) 3.4 (0.2) 3.5 (0.2) 70.9 (0.3) 0.66
trans-16:1n7
Median, % of total fatty acids 0.03 0.04 0.06 0.07 0.1
Systolic BP, mm Hg† 126.7 (0.8) 127.3 (0.8) 126.2 (0.8) 123.7 (0.9) 125.2 (0.9) 0.03
Diastolic BP, mm Hg† 72.7 (0.4) 72.6 (0.4) 71.5 (0.4) 71 (0.5) 71.2 (0.4) <0.01
Triglycerides, mg/dL‡ 147.8 (3.5) 139.9 (3.7) 133.5 (3.3) 128.3 (4) 121.7 (4.1) <0.0001
HDL-C, mg/dL‡ 50.5 (0.5) 51.5 (0.5) 49.9 (0.5) 50.7 (0.7) 50.2 (0.6) 0.35
LDL-C, mg/dL‡ 113 (1.2) 118 (1.2) 118.9 (1.4) 118.6 (1.5) 118.0 (1.5) 0.04
Total:HDL-C‡ 4.06 (0.1) 4.1 (0.1) 4.2 (0.1) 4.1 (0.1) 4.1 (0.1) 0.91
CRP, mg/L§ 3.6 (0.2) 3.4 (0.2) 3.7 (0.3) 3.4 (0.3) 3.7 (0.3) 0.67
Values are mean (SE) determined using linear regression with robust variance estimators. Means are adjusted for ﬁeld center, age (years), sex, race/ethnicity (non-Hispanic whites, blacks,
Hispanics and Chinese Americans), education (<high school, high school, >high school), cigarette smoking (never, current or former smokers, and pack-years of cigarette smoking), alcohol
(g/day), physical activity (metabolic equivalents per minute/week), prevalent diabetes (yes, no) alcohol intake (g/day) and BMI (kg/m2). CVD indicates cardiovascular disease; BP, blood
pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BMI, body mass index; CRP, C-reactive protein.
*Tests for trend across quintiles were performed by assigning each participant the median fatty acid value in their quintile and modeling this variable as a continuous term.
†Included adjustment for antihypertensive medication use at baseline (yes/no).
‡Included adjustment for lipid-lowering medication use at baseline (yes/no).
§Included adjustment for anti-inﬂammatory medication at baseline (yes/no).
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14:0 and trans-16:1n7 (HR [95% CI] for each SD of 15:0 was
0.82 [0.64 to 1.05] for CVD and 0.82 [0.61 to 1.12] for CHD).
Inﬂuence of Potential Mediators
Additional adjustment for factors that could be potential
mediators or confounders, including BMI, prevalent diabetes,
lipid-lowering medication use, LDL cholesterol levels, and
antihypertensive medication use, did not materially change
the ﬁndings. For example, each 1–SD-unit difference in 15:0
was associated with 24% lower risk of CVD (HR 0.76, 95% CI
0.61 to 0.95) after adjusting for these mediators. Associa-
tions also remained unchanged in sensitivity analysis exclud-
ing participants with diabetes at baseline (data not shown).
Discussion
In this large prospective study among multiethnic US adults,
we found that higher plasma phospholipid 15:0 was
cross-sectionally associated with lower blood pressure and
lower plasma triglycerides and prospectively associated with
lower incidence of CVD and CHD events. Conversely, plasma
phospholipid 14:0 and trans-16:1n7 were not associated with
CVD risk. These ﬁndings were similar among men and women
and among whites, Hispanics, blacks, and Asians. Associa-
tions were robust to adjustment for a variety of sociodemo-
graphic, lifestyle, and dietary factors, in addition to other dairy
fatty acid biomarkers.
Among the biomarkers evaluated, 15:0 appeared to be the
better biomarker of dairy fat in MESA, which is consistent with
prior studies.8,32 We observed largest differences in plasma
15:0 in association with consumption of whole-fat dairy foods
such as butter, cheese, and whole-fat milk; more modest
differences with low-fat cheese; and no differences with
consumption of low-fat or skim milk, suggesting that plasma
15:0 proportions are speciﬁc to dairy fat intake rather than
overall dairy consumption. In contrast, plasma phospholipid
14:0 and trans-16:1n7 were weakly associated with dairy fat
intake in our cohort. And 14:0 can be endogenously
synthesized, so plasma phospholipid concentrations of this
fatty acid may be inﬂuenced by metabolic and genetic factors
in addition to dairy intake.12 In MESA, trans-16:1n7 was
associated with consumption of foods likely to contain
partially hydrogenated oils, suggesting it was more a biomar-
ker of trans-fat rather than of dairy fat intake.
Our ﬁndings do not support an adverse association of
dairy fat consumption, as reﬂected by plasma phospholipid
15:0, with incident CVD or CHD. In MESA, dairy fat
consumption could be a marker of other factors that beneﬁt
cardiovascular health, such as lower BMI, lower meat
consumption, less smoking, and lower prevalence of
diabetes. On the other hand, 15:0 remained independently
associated with lower cardiovascular risk after multivariable
adjustment for these factors. The relatively modest correla-
tions between circulating 15:0 and dairy foods may reﬂect
less-than-optimal dietary assessment using self-reported
measures. On the other hand, plasma phospholipid concen-
trations are not inﬂuenced by dietary intakes alone but rather
by biologic processes related to fatty acid absorption and
incorporation into lipid fractions. Thus, it is possible that
plasma phospholipid 15:0 is a biomarker of other, unknown
metabolic processes, rather than diet, that favorably inﬂu-
ence CVD risk. However, this fatty acid is not known to be
synthesized by humans.
Could 15:0 itself have protective effects on CVD risk?
Besides being substrates for energy production and storage,
fatty acids are major components of membrane and organelle
structure and function, are natural ligands of nuclear
receptors that regulate gene expression, and serve as
precursors for an array of bioactive lipid metabolites.
Although relative concentrations of this fatty acid in phos-
pholipids are less that 1% of total fatty acids measures, we
are increasingly aware that very small amounts of molecules
that have regulatory functions can be important to physiol-
ogy. For example, small increases in n-3 polyunsaturated fatty
acid concentrations have been shown to alter cellular and
organelle membrane ﬂuidity, improving protein function and
signaling events.33 The mechanisms through which circulating
15:0 may inﬂuence CVD have not been established; however,
it is possible that small changes in circulating levels of this
fatty may be biologically relevant. On the other hand, the
observed associations with 15:0 could also represent beneﬁts
of other components present in dairy fat or dairy foods in
general. Phospholipid 15:0 was most strongly associated with
intakes of whole-fat dairy foods rather than with dairy foods
in general. Associations were also unchanged after adjust-
ment for estimated dietary calcium, vitamin D, and phospho-
rous. Nonetheless, given the complex correlations and
interactions among diverse bioactive components present in
foods, the associations observed may reﬂect beneﬁcial
effects of dairy fats or dairy foods as a whole, rather than
its components in isolation. Our ﬁndings strongly support
the need to further investigate the biological effects of
dairy fat, dairy foods, and circulating 15:0 in the development
of CVD.
The inverse cross-sectional associations we found between
plasma phospholipid 15:0 and blood pressure are consistent
with previous observational studies of self-reported total dairy
and low-fat dairy intake,1,3,34 as well as blood pressure–
lowering effects of diet patterns rich in low-fat dairy.6
Investigators in previous studies have emphasized the role
of nonfat dairy components such as protein, lactopeptides,
and minerals, but the mechanisms underlying these
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associations remain unclear. The cross-sectional associations
observed in our study support a potential blood pressure–
lowering effect of dairy fat.
Our prospective ﬁndings using objective biomarkers are
consistent with ﬁndings for self-reported saturated fat intake
in MESA.26 Saturated fat from dairy, but not from other
sources, was associated with lower CVD incidence (per 5 g/
day of saturated fat from dairy; HR 0.79, 95% CI 0.68 to
0.92).26 To date, only 3 prospective and 1 retrospective study
have evaluated associations between dairy fat biomarkers and
CVD events. A recent nested case-control study including
2424 cases and 4930 controls found no association of
plasma 15:0 or 14:0 with CHD risk (OR [95% CI] 0.98 [0.89 to
1.09] and 0.97 [0.87 to 1.08] for 1–SD-unit increase in
plasma 15:0 and 14:0, respectively); however, this study did
not include adjustment for dietary confounders.14 Another
nested case-control study including 444 cases and 556
controls in Sweden found no signiﬁcant association between
Table 3. Incidence of CVD According to Plasma Phospholipid FA Biomarkers of Dairy Fat Consumption in the Multi-Ethnic Study of
Atherosclerosis (N=2837; 189 New Cases)
HR (95% CI) According to Sex-Speciﬁc Quintiles of Each FA Biomarker
P Trend
HR (95% CI) for
1–SD-Unit
Difference in FA
Concentrations1 2 3 4 5
14:0
Median, % total FA 0.17 0.21 0.26 0.30 0.38
Person-years of
follow-up
4272 4089 4249 3390 3571
Incident cases, n 38 35 42 38 36
Multivariate
adjusted
1.0 0.98 (0.62 to 1.57) 1.26 (0.80 to 1.98) 1.18 (0.73 to 1.89) 1.06 (0.65 to 1.74) 0.67 1.02 (0.87 to 1.20)
Multivariate and
plasma FA
adjusted
1.0 1.06 (0.66 to 1.70) 1.44 (0.90 to 2.29) 1.40 (0.86 to 2.28) 1.44 (0.84 to 2.46) 0.12 1.14 (0.96 to 1.36)
15:0
Median, % total FA 0.11 0.14 0.16 0.19 0.24
Person-years of
follow-up
4460 3738 4196 3637 3540
Incident cases, n 45 31 48 38 27
Multivariate
adjusted
1.0 0.71 (0.45 to 1.14) 0.93 (0.60 to 1.44) 0.85 (0.53 to 1.37) 0.55 (0.32 to 0.95) 0.06 0.81 (0.68 to 0.98)
Multivariate and
plasma FA
adjusted
1.0 0.69 (0.43 to 1.11) 0.86 (0.55 to 1.37) 0.78 (0.47 to 1.28) 0.47 (0.25 to 0.86) 0.03 0.76 (0.61 to 0.93)
trans-16:1n7
Median, % total FA 0.03 0.04 0.06 0.07 0.09
Person-years of
follow-up
4970 4404 3833 2801 3563
Incident cases, n 34 35 46 39 35
Multivariate
adjusted
1.00 1.05 (0.64 to 1.74) 1.27 (0.78 to 2.08) 1.36 (0.81 to 2.28) 0.99 (0.58 to 1.69) 0.88 0.97 (0.82 to 1.13)
Multivariate and
plasma FA
adjusted
1.00 1.13 (0.68 to 1.87) 1.47 (0.89 to 2.42) 1.61 (0.95 to 2.74) 1.22 (0.70 to 2.11) 0.35 1.03 (0.88 to 1.22)
CVD events consist of myocardial infarction (n=69), resuscitated cardiac arrest (n=5), deﬁnite (n=51) and probable (n=20) angina (if followed by revascularization), stroke (n=43), and other
atherosclerotic death (n=1); 1 SD=0.08%, 0.05%, and 0.03% difference in 14:0, 15:0, and trans-16:1n7 FA levels, respectively. Multivariate-adjusted model included ﬁeld center, age
(years), sex, race/ethnicity (non-Hispanic whites, blacks, Hispanics, and Chinese Americans), education (<high school, high school, >high school), cigarette smoking (never, current, or
former smokers and pack-years of cigarette smoking), alcohol (g/day), physical activity (active and inactive leisure in metabolic equivalents per minute/week), low- and whole-fat dairy
(servings/day), processed and unprocessed meat (servings/day), total energy intake (kcal/day), ﬁber (g/day), and fruits and vegetables (servings/day). Multivariate- and plasma FA–
adjusted model included all variables listed plus mutual adjustment for 14:0, 15:0, and trans-16:1n7. CVD indicates cardiovascular disease; HR, hazard ratio; FA, fatty acid.
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serum 15:0 and risk of myocardial infarction (OR [95% CI] for
1–SD-unit: 0.94 [0.72 to 1.24] and 0.56 [0.30 to 1.04] in men
and women, respectively).9 Similar ﬁndings were seen in a
retrospective case-control study evaluating 15:0 proportions
in adipose tissue and risk of nonfatal MI in Costa Rica (OR
[95% CI] for extreme quintiles: 0.95 [0.72 to 1.25]).13 A
nested case-control analysis in the Nurses’ Health Study
showed a positive association between concentrations of
plasma phospholipid 15:0 and risk of CHD (HR [95% CI] for
extreme tertiles: 2.36 [1.16 to 4.78]).8 In contrast, plasma
15:0 was associated with a lower risk of incident heart failure
in the Atherosclerosis Risk in Communities Study (HR [95% CI]
for extreme quintiles: 0.62 [0.38 to 1.02]; P-trend=0.04); no
signiﬁcant associations were seen for plasma phospholipid
14:0.15 Overall, these prior studies demonstrate mixed
results, with most ﬁnding no harmful associations of dairy
fat biomarkers. Our work builds upon and extends these
previous observations by providing prospective evidence from
a population-based study using objective measures of dairy
fat in a multiethnic US population.
Table 4. Incidence of CHD According to Plasma Phospholipid FA Biomarkers of Dairy Fat Consumption in the Multi-Ethnic Study of
Atherosclerosis (N=2837; 146 New Cases)
HR (95% CI) According to Sex-Speciﬁc Quintiles of Each FA Biomarker
P Trend
HR (95% CI) for
1–SD-Unit
Difference in FA
Concentrations1 2 3 4 5
14:0
Median, % total FA 0.17 0.21 0.26 0.30 0.38
Person-years of
follow-up
4309 4113 4271 3416 3602
Incident cases, n 25 27 33 30 26
Multivariate
adjusted
1.0 1.16 (0.67 to 2.02) 1.48 (0.86 to 2.53) 1.36 (0.78 to 2.37) 1.13 (0.63 to 2.03) 0.68 1.01 (0.84 to 1.21)
Multivariate and
plasma FA
adjusted
1.0 1.29 (0.74 to 2.25) 1.76 (1.02 to 3.06) 1.70 (0.95 to 3.02) 1.66 (0.87 to 3.14) 0.10 1.15 (0.94 to 1.41)
15:0
Median, % total FA 0.11 0.14 0.16 0.19 0.24
Person-years of
follow-up
4493 3748 4232 3680 3557
Incident cases, n 36 25 32 29 19
Multivariate
adjusted
1.0 0.68 (0.40 to 1.15) 0.68 (0.40 to 1.14) 0.70 (0.41 to 1.20) 0.41 (0.22 to 0.78) 0.01 0.74 (0.60 to 0.92)
Multivariate and
plasma FA
adjusted
1.0 0.66 (0.39 to 1.12) 0.63 (0.37 to 1.09) 0.64 (0.36 to 1.14) 0.35 (0.17 to 0.72) 0.01 0.70 (0.54 to 0.89)
trans-16:1n7
Median, % total FA 0.03 0.04 0.06 0.07 0.09
Person-years of follow-up 4987 4451 3859 2836 3577
Incident cases, n 29 24 38 23 27
Multivariate
adjusted
1.0 0.82 (0.46 to 1.45) 1.12 (0.65 to 1.92) 0.83 (0.45 to 1.52) 0.82 (0.45 to 1.49) 0.63 0.91 (0.75 to 1.10)
Multivariate and
plasma FA
adjusted
1.0 0.90 (0.51 to 1.59) 1.34 (0.77 to 2.33) 1.04 (0.56 to 1.94) 1.06 (0.57 to 1.97) 0.67 0.99 (0.82 to 1.20)
CHD events consist of myocardial infarction (n=69), resuscitated cardiac arrest (n=5), deﬁnite (n=51) and probable (n=20) angina (if followed by coronary revascularization), and CHD
death (n=1); 1 SD=0.08%, 0.05%, and 0.03% difference in 14:0, 15:0, and trans-16:1n7 FA levels, respectively. Model 1: ﬁeld center, age (years), sex, race/ethnicity (non-Hispanic whites,
blacks, Hispanics, and Chinese Americans), education (<high school, high school, >high school), cigarette smoking (never, current or former smokers, and pack-years of cigarette smoking),
alcohol (g/day), physical activity (active and inactive leisure in metabolic equivalents per minute/week), low- and whole-fat dairy (servings/day), processed and unprocessed meat
(servings/day), total energy intake (kcal/day), ﬁber (g/day), and fruits and vegetables (servings/day). Model 2: Model 1+mutual adjustment for 14:0, 15:0, and trans-16:1n7. CHD
indicates coronary heart disease; HR, hazard ratio; FA, fatty acid.
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Our study has several strengths. The use of plasma
phospholipid fatty acids provided objective biomarkers of
dairy fat intake. The prospective design of our study
established temporality and minimized the possibility of
reverse causation. The use of a cohort minimized potential
selection bias. The ethnic diversity of MESA allowed for study
of a greater range of dietary behaviors and susceptibility to
disease outcomes than more homogeneous cohorts. Dairy
intake in our cohort was similar to that of the US
population.35 Consistency in ﬁndings for men and women
and across race/ethnicity groups increased conﬁdence in the
validity and generalizability of our ﬁndings. Finally, multivar-
iate adjustment for demographic, lifestyle, and dietary factors
minimized the inﬂuence of confounding.
Our study also had potential limitations. Associations with
CVD risk factors were cross-sectional, limiting inference on
cause-and-effect relationships; however, these associations
were consistent with prospective analysis of CVD events in our
study. Both laboratory and biologic (ie, related to changes over
time) imprecision in measurement of dairy biomarkers would
result in misclassiﬁcation of exposure. Laboratory imprecision
was largest at low concentrations (eg, quintiles 1 and 2) but
would not materially affect comparisons of participants across
extreme quintiles. It was not possible to evaluate potential
inﬂuence of changes in dairy intake over time in our cohort,
which would be likely to be random in respect to CVD incidence
and could attenuate associations with circulating fatty acids.
Our study may be statistically underpowered to assess
moderate differences in associations, especially by race/
ethnicity. Finally, although we carefully adjusted for several
confounders, residual confounding, in particular by healthy
lifestyle factors associated with dairy intake, may have biased
associations with 15:0 away from the null.
In conclusion, our results show an inverse association
between plasma phospholipid 15:0, a biomarker of dairy fat,
and CVD risk factors and CVD incidence. Our data support the
need for further investigation of CVD effects of dairy fat,
dairy-speciﬁc fatty acids, and dairy products in general.
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